|
2024
|
Invention
|
Zika virus vaccine.
Described herein are Zika virus vaccines and compositions and methods of pro... |
|
|
G/S
|
Anti-viral pharmaceutical preparations; vaccines for human use |
|
|
G/S
|
Providing educational information in the field of Chikungunya disease awareness. |
|
|
G/S
|
Providing educational information in the field of
Chikungunya disease awareness. |
|
|
Invention
|
Immunogenic chikungunya compositions for administration to immunocompromised patients. The presen... |
|
|
Invention
|
Process for virus production in a bioreactor. The present invention relates to a virus production... |
|
2023
|
G/S
|
Pharmaceutical preparations, vaccines for human use. |
|
|
G/S
|
Pharmaceutical preparations, vaccines for human use. |
|
|
G/S
|
Pharmaceutical preparations, namely, vaccines for human use |
|
|
G/S
|
pharmaceutical preparations, namely, vaccines for human use |
|
|
Invention
|
Zika virus vaccine. Described herein are Zika virus vaccines and compositions and methods of prod... |
|
|
Invention
|
Clostridium difficile vaccine. The present invention relates to a lipidated immunogenic Clostridi... |
|
|
Invention
|
Inactivated sars-cov-2 virus vaccine. Described herein are SARS-CoV-2 vaccines and compositions a... |
|
|
Invention
|
Mutant fragments of ospa and methods and uses relating thereto.
The present invention relates to... |
|
2022
|
Invention
|
Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof.
This ... |
|
|
G/S
|
Pharmaceutical preparations for human and veterinary use for the treatment of autoimmune diseases... |
|
|
Invention
|
Inactivation process for viruses.
Described herein are methods for inactivation of viruses with ... |
|
2021
|
G/S
|
Pharmaceutical preparations for the treatment of infectious diseases, vaccines for human use |
|
|
Invention
|
Mutant fragments of ospa and methods and uses relating thereto. Borrelia infection and a method o... |
|
|
Invention
|
Cpg-adjuvanted sars-cov-2 virus vaccine. Described herein are CpG-adjuvanted SARS-CoV-2 vaccines ... |
|
|
Invention
|
C. difficile and uses thereof. C. difficile toxin A and/or toxin B. |
|
|
Invention
|
Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccines.
The i... |
|
|
Invention
|
Improved methods of producing a lipidated protein.
The present invention relates to method of pr... |
|
|
Invention
|
Improvements in vaccine formulations for medical use.
The present invention relates to an alumin... |
|
|
Invention
|
Compositions comprising three ospa fusion proteins for medical use.
The present invention relate... |
|
|
Invention
|
Improvements in vaccine formulations for medical use. The present invention relates to an aluminu... |
|
|
Invention
|
Improved methods of producing a lipidated protein. Clostridiumdifficiledifficile or hMPV and/or o... |
|
|
Invention
|
Compositions comprising three ospa fusion proteins for medical use. The present invention relates... |
|
|
Invention
|
Improved methods of producing a lipidated protein. The present invention relates to method of pro... |
|
|
Invention
|
Improvements in vaccine formulations for medical use. Clostridium difficileClostridium difficile ... |
|
|
Invention
|
Inactivated sars-cov-2 virus vaccine.
Described herein are SARS-CoV-2 vaccines and compositions ... |
|
|
Invention
|
Coronavirus vaccines comprising a tlr9 agonist.
The present disclosure relates to immunogenic co... |
|
|
G/S
|
Pharmaceutical preparations; Vaccines for human use. |
|
2020
|
Invention
|
Inactivation process for viruses. Described herein are methods for inactivation of viruses with h... |
|
|
Invention
|
Zika virus purification. Described herein are processes for purifying infectious Zika virus parti... |
|
|
Invention
|
Aluminum compounds for use in therapeutics and vaccines. The invention relates to means and metho... |
|
2019
|
G/S
|
Providing medical services and advice in the field of vaccines; Providing educational information... |
|
2018
|
Invention
|
Multivalent ospa polypeptides and methods and uses relating thereto. Borrelia infection. |
|
|
Invention
|
Multivalent ospa polypeptides and methods and uses relating thereto. The present invention relate... |
|
2017
|
Invention
|
Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccines. The in... |
|
2016
|
Invention
|
Zika virus purification. Described herein are improved purification methods for Zika virus vaccin... |
|
|
G/S
|
Pharmaceutical and veterinary preparations, namely, vaccines for prevention and treatment of infe... |
|
2013
|
G/S
|
Chemical and/or biological preparations used in industry,
science and agriculture including biot... |
|
|
G/S
|
Chemical and biological preparations used in industry, science and agriculture, namely, biotechno... |
|
2012
|
G/S
|
Chemical and/or biological preparations used in industry, science and agriculture including biote... |
|
2010
|
G/S
|
Vaccines for human use. |
|
2009
|
G/S
|
Vaccines for human use |
|
2008
|
G/S
|
Vaccines for human use. |
|
2006
|
G/S
|
[ Pharmaceutical preparations for the treatment of and/or prevention of disorders of the nervous ... |
|
2005
|
G/S
|
Chemicals and chemical preparations for use in immunostimulants and vaccines; biological preparat... |
|
|
G/S
|
Chemical and/or biological preparations for use in industry,
science and laboratories. Pharmaceu... |
|
2004
|
G/S
|
Chemical and/or biological preparations used in industry, science and laboratories. Pharmaceutica... |
|
2002
|
G/S
|
[ chemicals for use in the pharmaceutical industry to manufacture diagnostic and therapeutic biol... |
|
|
G/S
|
Pharmaceutical preparations. |
|
|
G/S
|
Pharmaceutical preparations for the prevention [ and treatment ] of disorders of the nervous syst... |
|
|
G/S
|
Pharmaceutical preparations, except those relating to the treatment of cardiovascular disorders. |
